

# hematologic MALIGNANCIES HOUSTON 2010

## DVD ORDER FORM

DVD	Content	AMOUNT	QUANTITY	SUB-TOTAL
1	Plenary Session I	\$30.00	_____	_____
2	Chronic Lymphocytic Leukemia Part I	\$30.00	_____	_____
3	Chronic Lymphocytic Leukemia Part II	\$30.00	_____	_____
4	Acute Lymphoblastic Leukemia	\$30.00	_____	_____
5	Myeloproliferative Disorders	\$30.00	_____	_____
6	Plenary Session II & Myelodysplastic Syndromes Part I	\$30.00	_____	_____
7	Myelodysplastic Syndromes Part II	\$30.00	_____	_____
8	Acute Myeloid Leukemia Part I	\$30.00	_____	_____
9	Acute Myeloid Leukemia Part II	\$30.00	_____	_____
10	Multiple Myeloma	\$30.00	_____	_____
11	Lymphoma	\$30.00	_____	_____
12	Chronic Myeloid Leukemia	\$30.00	_____	_____
13	Special Topics	\$30.00	_____	_____
Set	HM 2010 13-DVD Set	\$315.00	_____	_____
	<i>SAVE \$75 WHEN YOU BUY THE SET!</i>			
	<b>Sub-Total</b>		_____	_____
	Shipping (\$4.50/DVD or \$14.50/set)		_____	_____
	<b>Grand Total</b>		_____	_____



## PAYMENT INFORMATION

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_

Zip \_\_\_\_\_

Country \_\_\_\_\_

Phone \_\_\_\_\_

**SHIPPING ADDRESS**  Same as Above

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_

Zip \_\_\_\_\_

Country \_\_\_\_\_

## METHOD OF PAYMENT

AmEx  MC  Visa  Discover  
 Cash  Check

Credit Card # \_\_\_\_\_

CVV Code \_\_\_\_\_

Expiration \_\_\_\_\_

Amount to Charge \_\_\_\_\_

Signature \_\_\_\_\_

Return form to Belinda Melder via fax (281-292-4378) or email (bmelder@jwccinc.com)

## DVD CONTENT DETAILS

---

### DVD 1 - Plenary Session I

***Molecular Abnormalities and Gene Expression Changes in AML. Are we Ready for a Prognostic Molecular Prioritization? What is the impact on Personalized AML Therapy?***

Torsten Haferlach, MD

***CLL: How Much Progress? What is the Future?***

Michael J. Keating, MB, BS

***Close to the Cure in CML***

Moshe Talpaz, MD

---

### DVD 2 - Chronic Lymphocytic Leukemia, Part I

***FCR Now Frontline Therapy***

Michael Hallek, MD

***Do the Biologic Factors add any Significance over the Clinical and Classical Prognostic Factors?***

William Wierda, MD, PhD

***Role of Old and New Monoclonal Antibodies, Alone and in Combinations***

Jeffrey A. Jones, MD

***Novel Inhibitors of B-Cell Signaling***

Susan O'Brien, MD

***Transplant in CLL--When, How, and What to Expect***

Issa Khouri, MD

***What do the Genetics Tell us? Can we Translate the Findings into Therapies?***

Carlo M. Croce, MD

***Treatment in CLL - the Age Old Question***

Peter Hillmen, MD, PhD

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 3 - Chronic Lymphocytic Leukemia, Part II**

***Debate: Fludarabine vs. Chlorambucil. Is the Battle Over?***

*Chlorambucil – Still Not Bad*

Daniel Catovsky, MD, DSc, FMedSci

*Fludarabine the Winner*

Kanti Rai, MD

---

***IMiDs Combinations in CLL***

Alessandra Ferrajoli, MD

***How Can We Exploit the CLL Microenvironment?***

Jan A. Burger, MD, PhD

---

**DVD 4 – Acute Lymphoblastic Leukemia**

***Treatment of Adolescents and Young Adults – Pediatric versus Adult Regimens?***

Ching-Hon Pui, MD

***Monoclonal Antibodies in ALL Therapy – Any Progress?***

Deborah Thomas, MD

***Targeted Therapies in Ph-positive ALL: Which is the Best TKI? What is the Role of Chemotherapy?***

Farhad Ravandi, MD

***Minimal Residual Disease: What Does it Mean? Is it now a Therapeutic Target?***

Wendy Stock, MD

***Novel Drugs and Strategies in ALL: Breakthroughs on the Horizon?***

Susan O'Brien, MD

***Allogeneic SCT for ALL in CR1: Grounds for Optimism?***

Anthony H. Goldstone, FRCR(M)

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 5 – Myeloproliferative Disorders**

***Pathophysiology of MPDs and Role of JAK2 Mutations***

Ross L. Levine, MD

***JAK2 Inhibitors – Are they the Solution?***

Srdan Verstovsek, MD, PhD

***Role of IMiDs in Myelofibrosis***

Animesh Pardhanani, MD

***Interferon Alfa in PV and ET***

Jean-Jacques Kiladjian, MD, PhD

***Prognostic Factors and Models in PV, ET, and MF***

Francesco Passamonti, MD

---

**DVD 6 – Myelodysplastic Syndromes Part I**

***Progress with Epigenetic Therapy in MDS – Are We Stuck?***

Pierre Fenaux, MD, PhD

---

**Plenary Session II**

*Cure of Myeloma, A Personal Odyssey*

Bart Barlogie, MD

*Any Progress in MPDs?*

Ayalew Tefferi, MD

---

***Debate: Iron Chelation Therapy in MDS – Is it Useful?***

*Absolutely Necessary to Improve Outcome*

Luca Malcovati, MD

*No Data to Prove its Benefit*

Ayalew Tefferi, MD

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 7 - Myelodysplastic Syndromes Part II**

***SNPs and other Molecular Changes in MDS – Ready for Primetime?***

Jaroslav P. Maciejewski, MD, PhD, FACP

***Novel Pathophysiologic Pathways in MDS***

Benjamin Ebert, MD, PhD

***IMiDs in MDS -- What Have We Learned So Far?***

Mikkael A. Sekeres, MD, MS

***Prognostic Factors and Risk Models in MDS***

David P. Steensma, MD, FACP

---

***Debate: Role of Allogeneic SCT in MDS***

*Critical to Cure MDS*

Theo de Witte, MD, PhD

*Minimal Benefit in MDS*

Guillermo Garcia-Manero, MD

---

***Novel Agents and Strategies in MDS***

Stefan Faderl, MD

***Growth Factors (EPO, GCSF, TPO) in the Modern Era***

Eva S. Hellström-Lindberg, MD, PhD

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 8 – Acute Myeloid Leukemia Part I**

***State of the Art Therapy of Younger AML – Lesson from Large Randomized Clinical Trials***

Stefan Faderl, MD

---

***Debate: Treatment of Older AML***

*Intensive Chemotherapy is the Best Approach*

Gunnar Juliusson, MD

*Low Intensity Therapy is the Way of the Future*

Alan K. Burnett, MD

---

***State of the Art Therapy of APL – The Lo Coco Approach***

Francesco Lo Coco, MD

***Role of Allogeneic SCT in CR1***

Frederick R. Appelbaum, MD

***FLT3 Mutations and FLT3 Inhibitors – Last Nail in Coffin or Resuscitation***

Mark Levis, MD, PhD

***New Treatments and Strategies in AML***

Farhad Ravandi, MD

---

**DVD 9 - Acute Myeloid Leukemia Part II**

***Marrow Microenvironment and Targeted Therapies***

Marina Konopleva, MD, PhD

***Micro RNA and Molecular Profiling in AML – Is it Relevant?***

Guido Marcucci, MD

***WBC Transfusions, Irradiated, Unirradiated?***

Gloria N. Mattiuzzi, MD

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 10 – Multiple Myeloma**

***Pathophysiology of Myeloma – Lessons into the Clinic***

Kenneth C. Anderson, MD

***SCT Improves Outcome in Myeloma***

Bart Barlogie, MD

***Novel Agents and Combinations in Myeloma***

Antonio Palumbo, MD

***Adverse Cytogenetic and Biologic Factors in Myeloma***

Sagar Lonial, MD

***IMiDs, Proteasome Inhibitors, Combos. What is Best?***

Robert Z. Orlowski, MD, PhD

***Waldenstrom's Macroglobulinemia – Where does Therapy Stand?***

Irene M. Ghobrial, MD

---

**DVD 11 - Lymphoma**

***Any Progress Since R-CHOP?***

John Sweetenham, MD

***Is Bendamustine + Rituxan the Best Treatment for Indolent Lymphoma?***

Mathias J. Rummel, MD, PhD

***What is Optimal Therapy in Early Large Cell Lymphoma?***

Fredrick B. Hagemeister, MD

***Indolent Lymphomas – Observe, BR, RCHOP, Others?***

Peter McLaughlin, MD

***Hodgkin's Disease – Cured but not Conquered***

Anas Younes, MD

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 12 – Chronic Myeloid Leukemia**

**Debate: What is the Ideal Frontline CML Therapy?**

*Imatinib*

Jane F. Apperley, MD

*2<sup>nd</sup> Generation TKIs*

Giuseppe Saglio, MD

---

**Salvage Strategies Post Imatinib Failure – What to do Now?**

Jorge E. Cortés, MD

---

**Debate: Optimal Monitoring in CML?**

*Intensive Monitoring is Essential*

Tim Hughes, MD, MBBS

*Too Much for Too Little*

Charles A. Schiffer, MD

---

**Debate: Role of Allogeneic SCT**

*As Salvage Post Imatinib Failure*

Richard Champlin, MD

*As Salvage Post 2 TKI Failures*

Elias Jabbour, MD

---

**Do We Have Better Prognostic Tools in CML?**

Michael Deininger, MD, PhD

**Can We Improve on Frontline CML Therapy?**

David Marin, MD

---

*hematologic*  
MALIGNANCIES  
HOUSTON 2010

---

**DVD CONTENT DETAILS (...cont'd)**

---

**DVD 13 – Special Topics**

***State of the Art New Antifungals***

Dimitrios Kontoyiannis, MD

***Allogeneic SCT in Leukemias – Overview***

Sergio Giralt, MD

***Multipotent Mesenchymal Stromal Cells (MSC) – Evolving Role in Cancer and Leukemia Therapy***

Michael Andreeff, MD, PhD

***Interesting Statistics in Leukemia***

Elihu H. Estey, MD